Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

What Was Tested

Researchers studied Liraglutide in this randomized controlled trial publication.

Who Took Part

According to the abstract, 451 subjects were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

Neither the subjects nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.

Groups ran in parallel: each of the subjects stayed in one arm throughout.

The primary endpoint was HbA1c change.

What Was Measured

The subject headings attached to it are Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Fasting, Glycated Hemoglobin, Hypoglycemia and Hypoglycemic Agents.

The authors tagged it with the keywords GLP-1 analogue, glycaemic control, incretin therapy, insulin therapy, randomised trial and weight loss therapy.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in 451 subjects.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Liraglutide compound page.